Overview

A Study to Compare Brachial Artery Reactivity and Cardiovascular Risk of a Treatment Simplification by Darunavir/Ritonavir (DRV/r) 800/100 mg Versus a Triple Combination Therapy Containing DRV/r in HIV-1 Infected Patients

Status:
Completed

Trial end date:
2011-04-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to compare change of brachial artery flow mediated vasodilatation using Darunavir/Ritonavir (DRV/r) 800/100 mg once daily as a monotherapy (use of a single medication) versus a triple combination therapy containing 2 nucleoside reverse transcriptase inhibitors (NRTIs) and DRV/r in Human immunodeficiency virus-1 (HIV-1) infected participants.

Phase:

Phase 2

Details

Lead Sponsor:

Janssen-Cilag S.p.A.

Treatments:

Darunavir
Reverse Transcriptase Inhibitors
Ritonavir